We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple, Inexpensive Genetic Test Can Identify MS Patients at Risk of Fatal Brain Infection

By LabMedica International staff writers
Posted on 20 Mar 2023

Patients with multiple sclerosis (MS) are confronted with a difficult decision - whether they should take medications that have proven to be effective in slowing the disease's progression, despite the potential risk of triggering a fatal brain infection called progressive multifocal leukoencephalopathy (PML). More...

This rare complication occurs when the JC virus, which is prevalent but usually dormant in most carriers, becomes active. Immune-modifying medications, including those prescribed for MS treatment, have been linked to PML in rare cases. As more potent immunosuppressive drugs become available, drug-induced PML is becoming increasingly common.

Now, leading MS experts are recommending genetic testing to identify MS patients with an increased likelihood of experiencing serious medication side effects. Joseph Berger, MD, MS Division Chief at the University of Pennsylvania Perelman School of Medicine (Philadelphia, PA, USA), and Hans-Peter Hartung, MD, Neurology Chair of Heinrich Heine University (Düsseldorf, Germany), have come out in support of a new study that confirms a strong link between four genetic mutations and PML. These mutations were found to be significantly more common in MS patients who took PML-linked drugs and later developed PML compared to those who took similar medications but did not develop PML.

"The availability of a simple, relatively inexpensive test that can identify the genes that put one at risk for PML would be enormously helpful in the management of patients. The widespread use of such testing could potentially allow the physician to use alternative therapies that do not carry the same risk of PML," stated Drs. Berger and Hartung.

Related Links:
University of Pennsylvania Perelman School of Medicine
Heinrich Heine University


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Gold Member
Hematology System
Medonic M16C
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.